ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,431.60
-0.04%
Dow Jones
38,589.16
-0.15%
US Dollar vs MXN
18.4648
0.00%
Brent Oil
82.275
0.00%
Bitcoin
66,639.79
0.68%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NYSE
  6. Annovis Bio Inc (ANVS)

  7. Annovis Bio Inc (ANVS) Noticias

ANVS Annovis Bio Inc

5.85
-0.16 (-2.66%)
14 Jun 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Annovis Bio Inc ANVS NYSE Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
-0.16 -2.66% 5.85 17:14:47
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
6.26 5.85 6.26 5.85 6.01
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
13/6/202405:05EDGAR2Form 8-K - Current report
11/6/202416:00EDGAR2Form 8-K - Current report
05/6/202415:32EDGAR2Form 8-K - Current report
21/5/202415:05EDGAR2Form 8-K - Current report
21/5/202406:30GLOBEAnnovis Announces New Publication in a Peer-Reviewed Journal
13/5/202415:05EDGAR2Form 8-K - Current report
13/5/202406:30GLOBEAnnovis Bio Provides Corporate Updates and Announces First..
10/5/202416:11EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202415:03EDGAR2Form 8-K - Current report
09/5/202406:30GLOBEAnnovis Announces Unblinding of the Buntanetap Phase III..
06/5/202416:12EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
06/5/202416:11EDGAR2Form 8-K - Current report
06/5/202406:30GLOBEAnnovis Bio CEO Maria Maccecchini Issues Letter to..
29/4/202409:10GLOBEAnnovis Bio Announces Statistically Significant Phase II/III..
02/4/202406:30GLOBEAnnovis Bio Provides Corporate Updates and Reports Fourth..
28/2/202406:08IHMARKETNEWSUS Stock Movers Before Market: Beyond Meat, eBay, First..
12/2/202413:00EDGAR2Form S-3/A - Registration statement under Securities Act of..
01/2/202415:05EDGAR2Form S-3 - Registration statement under Securities Act of..
22/11/202315:27EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
21/11/202313:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202313:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202313:29EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/11/202313:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/11/202315:45EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
02/11/202306:30BWAnnovis Bio Measures Novel Biomarkers in Plasma of..
01/11/202311:28EDGAR2Form 8-K - Current report
01/11/202311:24EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
31/10/202307:00BWAnnovis Bio Announces Pricing of $7.5 Million Public..
30/10/202316:27EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
30/10/202316:17EDGAR2Form 8-K - Current report
30/10/202315:48BWAnnovis Bio Announces Launch of Proposed Public Offering
30/10/202315:42BWAnnovis Bio Receives Positive Recommendation to Continue..
24/10/202308:13BWAnnovis Bio Showcases Promising Progress in Novel Drug..
21/9/202308:35GLOBEDawson James Securities Announces October Date for 8th..
15/8/202306:20BWAnnovis Bio Announces Second Quarter 2023 Financial Results..
14/8/202315:40EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
18/7/202307:18BWContinued Positive Performance of Novel Drug Development by..
27/6/202306:30BWAnnovis Bio Announces the Filing of a Groundbreaking Patent
20/6/202311:05BWAnnovis Bio Receives Excellent Safety Rating and Positive..

Su Consulta Reciente

NYSE
ANVS
Annovis Bio
USOTC
YLLWF
Yellow Hat (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados